![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bentley Gets Approval to Market Generic Version of Omeprazole in the UK
Bentley Gets Approval to Market Generic Version of Omeprazole in the UK
May 20, 2005
Bentley Pharmaceuticals, a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, has announced that its 20-mg generic dosage version of omeprazole has been approved for marketing in the UK.
Omeprazole belongs to a class of proton-pump inhibitors used in the treatment of acid-related gastrointestinal disorders. The product is marketed by AstraZeneca in Europe under the trade name Losec and in the U.S. under the trade name Prilosec.
The company has entered into agreements with multiple distributors and has licensed the product through its Spanish subsidiary, pending regulatory approval. The product is being launched immediately in the UK market.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct